Targets Greater China private equity opportunities across growth-stage technology, consumer and healthcare companies, deploying equity and structured capital through direct investments and co-investments for institutional and family-office clients. The firm leverages Hong Kong as a regional base to source cross-border deal flow between mainland China and global investors, emphasizing operational support, follow-on funding and exit preparation via strategic trade buyers or IPOs.
Targets Greater China private equity opportunities across growth-stage technology, consumer and healthcare companies, deploying equity and structured capital through direct investments and co-investments for institutional and family-office clients. The firm leverages Hong Kong as a regional base to source cross-border deal flow between mainland China and global investors, emphasizing operational support, follow-on funding and exit preparation via strategic trade buyers or IPOs.
Operates as a Greater China growth private equity allocator that prioritizes technology, consumer and healthcare leaders with clear paths to scalable revenue and cross-border expansion. Capital deployment blends direct equity, structured instruments and co‑investments to balance upside and downside protection, with staged follow‑on reserves for operational scale. Underwriting emphasizes revenue growth, unit economics, founder alignment and exit-readiness via trade sales or Hong Kong/China IPOs. Typical horizon is 3–7 years with active governance and operational support.
Operates as a Greater China growth private equity allocator that prioritizes technology, consumer and healthcare leaders with clear paths to scalable revenue and cross-border expansion. Capital deployment blends direct equity, structured instruments and co‑investments to balance upside and downside protection, with staged follow‑on reserves for operational scale. Underwriting emphasizes revenue growth, unit economics, founder alignment and exit-readiness via trade sales or Hong Kong/China IPOs. Typical horizon is 3–7 years with active governance and operational support.
| Trades 17 | Longs Won 5/17 29% | Profit Factor 3.51 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $5.39M |
| Average Win $6.44M | Best Trade (Dec 31) $16.69M | Sharpe Ratio -8.44 |
| Average Loss -$765,035.71 | Worst Trade (Sep 29) -$5.93M | Z-Score 1.49 (86.46%) |
| Commissions $0 | Avg. Trade Length 6m 5d | Expectancy $1.57M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ | ∞ |